ClinicalTrials.gg

TargetBeta

CD274

CD274 molecule · also B7-H, B7H1, PD-L1, PDL1 · CD molecules

19 programs in company-led studies act on CD274, from 15 companies: 12 in phase 3, 1 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (14 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
durvalumabruleAstraZenecaphase 410247 running–NCIt
adebrelimabruleJiangsu HengRui Medicinephase 35140 running–NCIt
pumitamigBioNTechphase 33432 runningVEGFAa judged reading
Anti-PD-L1 Antibody-drug Conjugate HLX43Fosun Pharmaphase 31717 running–the company's pipeline
Anti-PD-L1/4-1BB Bispecific Antibody LBL-024ruleNanjing Leads Biolabsphase 31010 runningTNFRSF9NCIt
benmelstobartruleSino Biopharmaceuticalphase 3339 running–NCIt
retlirafusp alfaruleJiangsu HengRui Medicinephase 3206 runningTGFB1NCIt
sotiburafusp alfaruleHuabo Biopharmphase 354 running–NCIt
erfonrilimabruleAlphamab Oncologyphase 3142 runningCTLA4NCIt
socazolimabruleLee's Pharmaceuticalphase 392 running–NCIt
fetrastobart vedotinPfizerphase 322 running–the company's pipeline
HLX37Fosun Pharmaphase 322 runningVEGFAthe company's pipeline
acasunlimabruleGenmabphase 361 runningTNFRSF9NCIt
PD-L1 Inhibitor ABSK043ruleAbbisko Caymanphase 255 running–NCIt
Anti-PD-L1/Anti-VEGF Bispecific Antibody AP505ruleChina Resources Pharmaceutical Groupphase 244 running–NCIt
Anti-PD-L1/Anti-Vd1 T-cell Engager TAK-505ruleTakedaphase 211 runningTRDV1NCIt
Anti-CD137/PD-L1 Bispecific Antibody FS222Sino Biopharmaceuticalphase 111 runningTNFRSF9the company's pipeline
Anti-NKG2A/Anti-PD-L1 Bispecific Antibody XB628ruleExelixisphase 111 runningKLRC1NCIt
PD-L1-directed TLR7 Agonist PF-08046037rulePfizerphase 110 running–NCIt

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.